Conferences

News & Press

The power and cost-effectiveness of AI are calling into question many of our assumptions about healthcare.   The most important dichotomy proving to be false is that providing the latest and most thorough diagnostic technology to optimize clinical outcomes is more expensive.  When we use AI to more comprehensively analyze cases we benefit from Moore’s law rapidly and continuously reducing costs.  By contrast, hospital-based care, especially when in an intensive setting such as the NICU is continuously increasing in cost. It is not surprising that when more extensive testing produces clinically actionable results that actually decrease hospital costs we can accomplish the holy grail — better and less expensive simultaneously.

Read More

Fabric Genomics and TOMA Biosciences announced a partnership in April to develop an end-to-end genomic testing and clinical interpretation product for somatic cancers. The new system integrates TOMA’s oligo selective sequencing (OS-Seq) technology, which was developed at Stanford University, and combines it with Fabric Genomics’ bioinformatics platform. “What TOMA does is a very specialized assay …

Read More